Resonance Health Limited (ASX:RHT)
Resonance Health Limited is an Australian healthcare company. The Company is focused on the development and commercialization of technologies and services for the analysis of radiological images. The Company's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan uses Artificial Intelligence (AI) as an automated software medical device to determine liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The Company product HepaFat-Scan is a non-invasive MRI-based solution for measuring the volume fraction of fat in liver tissue. HepaFat-Scan is a medical device software, which is fully automated and uses Artificial Intelligence (AI) to assess liver fat. HepaFat-AI assesses and reports the volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF), and steatosis grade in individuals with suspected fatty liver disease.